查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1198127

前列腺癌诊断和治疗市场 - 增长、趋势、COVID-19 影响和预测 (2023-2028)

Prostate Cancer Diagnostics and Therapy Market - Growth, Trends, and Forecast (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 124 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

在预测期内，前列腺癌诊断和治疗市场预计将以约 13.7% 的复合年增长率增长。

由于诊断程序和外科手术的暂停，突然出现的 COVID-19 感染影响了癌症诊断和治疗护理。 此外，许多研究表明，癌症患者，尤其是前列腺癌患者，由于其恶性肿瘤和化疗引起的免疫抑制状况，比未患癌症的人更容易感染冠状病毒。我在这里。 因此，首要建议是居家休息，避免非紧急诊治。 根据美国国际癌症控制联盟 (UICC) 2020 年 5 月的数据，美国的癌症诊断率在大流行期间显着下降。 癌症诊断的这种下降预计将导致大流行期间需求的短期下降。 然而，放宽严格的规定有望重新开放前列腺癌诊断诊所和研究活动，这有望促进大流行后时期的市场增长。

人口老龄化和前列腺癌的高患病率是推动所研究市场增长的主要因素。 根据 Globocan 2020，前列腺癌是男性中第二常见的癌症类型。 同一来源发布的数据显示，前列腺癌的患病率为 1,414,259，占全世界所有癌症患者的 7.3%。 由于前列腺癌在老年人中更为常见，预计全球人口老龄化也将推动市场增长。 例如，根据联合国公布的《2022年世界人口展望》，世界65岁及以上人口的比例预计将从2022年的10%上升到2050年的16%。 预计在预测期内，易患前列腺癌的老龄化人口的增加将推动市场增长。

此外，不断增加的产品批准和开发预计将有助于所研究市场的增长。 例如，2022 年 3 月，美国食品和药物管理局批准Novartis的 Pluvicto（橹 Lu 177）用于治疗患有特定类型晚期癌症的成年患者，该癌症称为前列腺特异性膜抗原阳性转移性去势抵抗性前列腺癌。 vipivotide tetraxetan)。 因此，这些将导致前列腺癌药物的采用增加，并将推动市场增长。

因此，预计市场将在上述所有因素的推动下保持高速增长。 然而，前列腺癌药物的高价格和低临床试验成功率预计会阻碍市场增长。

前列腺癌诊疗市场趋势

经直肠超声 (TRUS) 细分市场预计在预测期内快速增长

预计在预测期内，经直肠超声将占据很大的市场份额。 经直肠超声 (TRUS) 引导的活检也是前列腺癌的常见诊断程序之一，仍然被认为是一种可行的选择。 这是大多数泌尿科医生都熟悉的技术，尿潴留的风险低，并且对捐献者来说快速方便。 对观察前列腺的异常部位、大小、形状非常有用。 在某些情况下，TRUS 被认为是一种可行的选择，作为早期检测前列腺癌的重要替代方法。 对于因幽闭恐惧症、金属植入物或保险范围而无法接受 MRI 程序的患者，TRUS 是具有临床益处的良好选择，从而有助于研究领域的发展。

此外，2022 年 2 月发表在《泌尿外科杂誌》上的一项研究发现，TRUS 活检呈阴性的男性，尤其是前列腺特异性抗原 (PSA) 为 10 或以下的男性，更有可能死于前列腺癌-特定死亡率。已知极低。 出于这个原因，广泛使用 MRI 靶向进行初始前列腺活检非常令人担忧，我们建议 MRI 靶向应仅限于活检阴性后 PSA 为 10 ng/ml 或更高的男性。我在这里. 这将推动采用经直肠超声检测前列腺癌，推动这一领域的增长。

此外，不断增加的产品发布预计将有助于所研究细分市场的增长。 例如，2021 年 5 月，RSIP Vision 推出了一种新的前列腺 MRI 到超声配准工具，该工具使用标准 MRI 扫描和经直肠超声图像提供 MRI 到超声配准。。 由于在前列腺癌检测中越来越多地采用经直肠超声，此类先进的解决方案将进一步推动这一领域的增长。

在某些情况下，患者通常患有相关疾病，而 TRUS 活检与其他程序相比具有显着优势。 因此，TRUS 广为人知并被接受。 现在正在出现几种新的图像处理方法，并且预计在预测期内该领域的增长将加速。

预计在预测期内北美将保持重要的市场份额

由于前列腺癌患病率上升、意识提高和该地区研发增加等因素，预计北美将占据很大的市场份额。 据美国癌症协会估计，到 2022 年，美国将发现并报告 268,490 例新的前列腺癌病例。 根据同一数据，每 10 名男性中就有 6 人在 65 岁以上被诊断出患有该病，而在 40 岁以下的男性中则很少见。 诊断时男性的平均年龄约为 66 岁。 前列腺癌的这种发病率预计将有助于该地区的市场增长。

美国食品和药物管理局正在采取措施批准临床阶段的药物并加速临床开发，以推动癌症治疗市场的增长。 公司和研究机构正在投资研发，为市场的增长做出贡献。

前列腺癌患病率上升为市场参与者提供了重要机会。 主要市场参与者正在集中精力进行研发，以将新的可靠疗法推向市场。 例如，在 2021 年 9 月，美国食品和药物管理局将允许检查身体组织的医疗专业人员（病理学家）作为辅助审查来自前列腺活检（从身体移除的组织）的数字扫描幻灯片的许可软件来帮助检测区域疑似癌症。 预计这些努力将促进在美国引入诊断和治疗前列腺癌，并成为市场增长的推动力。

北美市场参与者正在关注各种增长战略，例如新产品发布、合作伙伴关係、兼併和收购。 例如，2021 年 9 月，Page 获得了 USFDA 的批准，可以从头营销 PaigeProsate，这是一种用于前列腺癌检测的临床级 AI 解决方案。 同样在 2021 年 1 月，Myovant 与Pfizer公司合作开始商业化 Orgovyx（relugolix），这是一种前列腺癌治疗药物，于 2020 年 12 月获得批准。

因此，预计上述因素将在预测期内推动该地区的市场。

前列腺癌诊断和治疗市场竞争对手分析

由于市场进入者众多，前列腺癌诊断和治疗市场竞争激烈。 全球前列腺癌诊断和治疗市场包括几家大型製药和设备製造商，主要参与者主要位于特定产品市场。 市场上的主要参与者包括Abbott Laboratories、Astellas Corporation、AstraZeneca、Bayer Healthcare AG、Cellanyx Diagnostics Inc、Dendreon Corporation、Ferring Pharmaceuticals、Ipsen Group、Sanofi-Aventis、Tolmar Inc、GE Healthcare、Siemens Healthineers、F. Hoffmann - La Roche。

其他好处

  • Excel 格式的市场预测 (ME) 表
  • 3 个月的分析师支持

内容

第一章介绍

  • 研究假设和市场定义
  • 调查范围

第二章研究方法论

第 3 章执行摘要

第四章市场动态

  • 市场概览
  • 市场驱动力
    • 老龄化社会和前列腺癌的高患病率
    • 药物创新和基因组学/蛋白质组学开发
    • 提高政府对癌症认识的举措
  • 市场製约因素
    • 前列腺癌药物的高成本
    • 临床试验成功率低
  • 波特的五力分析
    • 新进入者的威胁
    • 买方/消费者议价能力
    • 供应商的议价能力
    • 替代品的威胁
    • 竞争公司之间的敌对关係

第 5 章市场细分（基于价值的市场规模：百万美元）

  • 按类型
    • 良性前列腺增生症
    • 前列腺癌
    • 小细胞癌
    • 其他类型
  • 按方式
    • 诊断名称
      • 组织活检
      • 经直肠超声检查
      • 实验室测试
      • 前列腺特异性抗原检测
      • 尿检
      • 影像诊断
    • 治疗
      • 手术
      • 放射治疗
      • 治疗药物
      • 激素疗法
      • 化疗
      • 其他治疗
  • 按地区
    • 北美
      • 美国
      • 加拿大
      • 墨西哥
    • 欧洲
      • 德国
      • 英国
      • 法国
      • 意大利
      • 西班牙
      • 其他欧洲地区
    • 亚太地区
      • 中国
      • 日本
      • 印度
      • 澳大利亚
      • 韩国
      • 其他亚太地区
    • 中东
      • 海湾合作委员会
      • 南非
      • 其他中东地区
    • 南美洲地区
      • 巴西
      • 阿根廷
      • 其他南美洲

第六章竞争格局

  • 公司简介
    • Abbvie Inc.
    • Astellas Pharma Inc.
    • AstraZeneca PLC
    • Bayer AG
    • F. Hoffmann-La Roche Ltd
    • Ipsen SA
    • Johnson & Johnson Services Inc.
    • Koninklijke Philips NV
    • Merck & Co. Inc.
    • Pfizer Inc.
    • Sanofi-Aventis
    • Thermo Fisher Scientific

第七章市场机会与未来趋势

简介目录
Product Code: 47468

The prostate cancer diagnostics and therapy market was expected to register a CAGR of nearly 13.7% during the forecast period.

Cancer diagnosis and treatment care were impacted by the sudden emergence of COVID-19 infection due to the halt in diagnostic procedures and surgical procedures. Moreover, as per many studies, cancer patients, especially prostate cancer patients, are more susceptible to coronavirus than individuals without cancer, as they are in an immunosuppressive state caused by malignancy and anticancer treatment. Thus, they are majorly suggested to stay at home and avoid all non-emergent diagnoses and treatment. According to the Union for International Cancer Control (UICC) in May 2020, there is a significant decrease in cancer diagnostics rates in the United States during the pandemic. Such decreases in cancer diagnostics are expected to have a short-term decline in demand during the pandemic period. However, the relaxation of the strict regulations is expected to contribute to the reopening of diagnostic clinics and research activities for prostate cancer, thereby contributing to the growth of the market during the post-pandemic period.

The major factor attributing to the growth of the market studied is an aging population and a high prevalence rate of prostate cancer. According to Globocan 2020, prostate cancer is the second most common type of cancer in the male population. As per the data published by the same source, the prevalence of prostate cancer was found to be 1,414,259, or 7.3% of the total cancer cases worldwide. As prostate cancer is more common in the elderly population, the rising aging population in the world is also expected to propel market growth. For instance, according to the World Population Prospects 2022 published by the United Nations, the share of global population aged 65 years or above is projected to rise from 10% in 2022 to 16% in 2050. Such an increase in the geriatric population who are prone to developing prostate cancer is expected to drive the growth of the market over the forecast period.

Furthermore, the rising product approvals and developments are expected to contribute to the growth of the studied market. For instance,in March 2022, the United States Food and Drug Administration approved Novartis's Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for the treatment of adult patients with a certain type of advanced cancer called prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer. Therefore, these will lead to increased adoption of prostate cancer therapies, driving market growth.

Hence, owing to all the aforementioned factors, the market is anticipated to propel at high growth rates. However, the high cost of prostate cancer drugs and the low success rate of clinical trials are expected to hinder market growth.

Prostate Cancer Diagnostics & Therapy Market Trends

The Transrectal Ultrasound (TRUS) Segment is Expected to Grow at Rapid Pace Over the Forecast Period

Transrectal ultrasound is expected to hold a significant share of the market over the forecast period. The transrectal ultrasound (TRUS) guided biopsy is also among the common diagnostic procedures performed for prostate cancer, which is still considered a viable option. It is quick and convenient to the provider, with a familiar approach to most urologists and a low risk of urinary retention. It is very useful to observe the abnormal areas of the prostate, size, and shape of the prostate. TRUS is considered a viable option in some cases as an important alternative for the early detection of prostate cancer. For patients who cannot undergo MRI procedures due to claustrophobia, metal implants, or lack of insurance coverage, TRUS is a good option with clinical benefits, thereby contributing to the growth of the studied segment.

Furthermore, according to the study published in the Journal of Urology, in February 2022, men who have negative TRUS biopsies have an extremely low prostate cancer-specific death rate, especially if their prostate-specific antigen (PSA) is below 10. This raises major concerns regarding the widespread use of MRI-targeting for the first prostate biopsy and advises that MRI-targeting should be reserved for men whose PSA is greater than 10 ng/ml following a negative biopsy. This will lead to increased adoption of transrectal ultrasound for the detection of prostate cancers, thereby driving this segment's growth.

In addition, the rising product launches are expected to contribute to the growth of the studied segment. For instance, in May 2021, RSIP Vision launched a new prostate MRI-to-ultrasound registration tool that provides MRI-to-ultrasound registration using standard MRI scans and trans-rectal ultrasound images. Such advanced solutions will further drive this segment's growth due to the increased adoption of transrectal ultrasound diagnostics in the detection of prostate cancers.

In several cases, the patients often suffer from associated diseases, where the TRUS biopsy has a considerable edge over other procedures. Thus, it is widely known and accepted. At present, with several new approaches coming up with imaging, the growth of this segment is estimated to be rapid during the forecast period.

North America is Expected to Retain a Significant Market Share During the Forecast Period

North America is anticipated to hold a significant market share, owing to the factors such as the increasing prevalence of prostate cancer, coupled with the rising awareness and increasing research and development in this region. According to the American Cancer Society, in 2022, an estimated 268,490 new prostate cancer cases was identified were and reported in the United States. In addition according to the same source, about 6 cases in 10 are diagnosed in men who are 65 or older, and it is rare in men under 40. The average age of men at diagnosis is about 66. Such an incidence of prostate cancer is expected to contribute to the growth of the market in this region.

The United States Food and Drug Administration is taking steps to enhance the growth of the cancer therapy market by approving drugs, which are in the clinical phase, thus accelerating clinical developments. Companies and research organizations are investing in research and development (R&D), thereby contributing to the growth of the market.

The rising number of prostate cancer cases is creating huge opportunities for market players. The major market players are focusing on R&D activities to bring new and reliable treatments to the market. For instance, in September 2021, the United States Food and Drug Administration authorized the marketing of software to assist medical professionals who examine body tissues (pathologists) in the detection of areas that are suspicious for cancer as an adjunct (supplement) to the review of digitally-scanned slide images from prostate biopsies (tissue removed from the body). Such initiatives will lead to increased adoption of prostate cancer diagnosis and treatment in the United States, thereby driving market growth.

Market players in North America are focusing on various growth strategies such as new product launches, partnerships, mergers, and acquisitions. For instance, in September 2021, Paige received USFDA approval for the de novo marketing of PaigeProsate, a clinical-grade AI solution for prostate cancer detection. In addition, in January 2021, Myovant partnered with Pfizer to commercialize its prostate cancer drug Orgovyx (relugolix), approved in December 2020.

Therefore, owing to the above-mentioned factors, the market is expected to drive in this region over the forecast period.

Prostate Cancer Diagnostics & Therapy Market Competitor Analysis

The market for prostate cancer diagnostics and therapy is highly competitive due to the presence of a number of market players. Several large drug and equipment manufacturers exist within the global prostate cancer diagnostic and therapy market, and their status as major players lies primarily within specific product markets. Some of the key players in the market include Abbott Laboratories, Astellas Inc., AstraZeneca, Bayer HealthCare AG, Cellanyx Diagnostics Inc., Dendreon Corporation, Ferring Pharmaceuticals, Ipsen Group, Sanofi-Aventis, Tolmar Inc, GE Healthcare, Siemens Healthineers, and F. Hoffmann-La Roche AG.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Aging Population and High Prevalence Rate of Prostate Cancer
    • 4.2.2 Innovation in Drugs and Developments in Genomics and Proteomics
    • 4.2.3 Increasing Government Initiatives for Cancer Awareness
  • 4.3 Market Restraints
    • 4.3.1 High Cost of Prostate Cancer Drugs
    • 4.3.2 Low Success Rate of Clinical Trials
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Type
    • 5.1.1 Benign Prostatic Hyperplasia
    • 5.1.2 Prostatic Adenocarcinoma
    • 5.1.3 Small Cell Carcinoma
    • 5.1.4 Other Types
  • 5.2 By Modality
    • 5.2.1 Diagnosis
      • 5.2.1.1 Tissue Biopsy
      • 5.2.1.2 Transrectal Ultrasound
      • 5.2.1.3 Clinical Laboratory Examination
      • 5.2.1.3.1 Prostate-specific Antigen Testing
      • 5.2.1.3.2 Urine Testing
      • 5.2.1.4 Diagnostic Imaging
    • 5.2.2 Treatment
      • 5.2.2.1 Surgery
      • 5.2.2.2 Radiation Therapy
      • 5.2.2.3 Therapeutics
      • 5.2.2.3.1 Hormone Therapy
      • 5.2.2.3.2 Chemotherapy
      • 5.2.2.3.3 Other Treatments
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Abbvie Inc.
    • 6.1.2 Astellas Pharma Inc.
    • 6.1.3 AstraZeneca PLC
    • 6.1.4 Bayer AG
    • 6.1.5 F. Hoffmann-La Roche Ltd
    • 6.1.6 Ipsen SA
    • 6.1.7 Johnson & Johnson Services Inc.
    • 6.1.8 Koninklijke Philips NV
    • 6.1.9 Merck & Co. Inc.
    • 6.1.10 Pfizer Inc.
    • 6.1.11 Sanofi-Aventis
    • 6.1.12 Thermo Fisher Scientific

7 MARKET OPPORTUNITIES AND FUTURE TRENDS